Antigen persistence and TLR stimulation contribute to induction of a durable HIV-1-specific neutralizing antibody response

Nat Commun. 2025 Jun 3;16(1):5162. doi: 10.1038/s41467-025-60481-2.

Abstract

HIV-1 Env glycoprotein (Env) immunogenicity is limited in part by structural instability and extensive glycan shielding and is likely the greatest obstacle to an HIV-1 vaccine. Stabilized Env trimers can elicit serum neutralizing antibodies, but the response is short-lived. Here we use Newcastle Disease Virus-like particle (NDV-VLP) platform to present stabilized versions of HIV-1 Env at high valency and in the context of varied conformational stability, adjuvants, dose, and antigen persistence. Influenza virus hemagglutinin, or SARS-CoV2 Spike-bearing VLPs rapidly induce neutralizing antibodies, in contrast, they were not induced by those bearing Env. A replicating adenovirus type 4 expressing Env rapidly induces autologous neutralizing antibodies. However, durable neutralizing antibodies are induced only when multiple features of a replicating virus infection are combined, with the largest impact from dose and escalating dose. In summary, we show here immunogenicity of HIV-1 Env could be improved by reproducing features of virus infection.

MeSH terms

  • AIDS Vaccines* / immunology
  • Animals
  • Antibodies, Neutralizing* / immunology
  • Female
  • HEK293 Cells
  • HIV Antibodies* / immunology
  • HIV Infections / immunology
  • HIV Infections / prevention & control
  • HIV-1* / immunology
  • Hemagglutinin Glycoproteins, Influenza Virus / immunology
  • Humans
  • Newcastle disease virus / genetics
  • Newcastle disease virus / immunology
  • SARS-CoV-2 / immunology
  • Spike Glycoprotein, Coronavirus / immunology
  • Vaccines, Virus-Like Particle / immunology
  • env Gene Products, Human Immunodeficiency Virus* / genetics
  • env Gene Products, Human Immunodeficiency Virus* / immunology

Substances

  • Antibodies, Neutralizing
  • env Gene Products, Human Immunodeficiency Virus
  • HIV Antibodies
  • AIDS Vaccines
  • Spike Glycoprotein, Coronavirus
  • Hemagglutinin Glycoproteins, Influenza Virus
  • Vaccines, Virus-Like Particle
  • spike protein, SARS-CoV-2